Risk of Stroke in Patients with Multiple Sclerosis Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)

被引：0
|
作者：
Sabido, Meritxell [1 ]
Venkatesh, Saritha [2 ]
Aldridge, Julie [2 ]
Gillett, Alan [3 ]
机构：
[1] Merck KGaA, Darmstadt, Germany
[2] EMD Serono Inc, Billerica, MA USA
[3] EMD Serono Inc, Mississauga, ON, Canada
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S36.008
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy
    Sandberg-Wollheim, Magnhild
    Alteri, Enrica
    Moraga, Margaretha Stam
    Kornmann, Gabrielle
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (04) : 423 - 430
  • [22] Infections in alemtuzumab patients previously treated with subcutaneous interferon beta-1a
    Lycke, J.
    Cohen, J. A.
    Fox, E. J.
    Hartung, H. -P.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    Compston, D. A. S.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 658 - 658
  • [23] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Gitlin, M.
    Snyder, S.
    Jhaveri, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S744 - S744
  • [24] PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS SUBCUTANEOUS INTERFERON BETA-1A IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Gitlin, M.
    Snyder, S.
    Jhaveri, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S746 - S746
  • [25] Real-world outcomes in patients with relapsing forms of multiple sclerosis treated with intramuscular interferon beta-1a or peginterferon beta-1a
    Salter, A.
    Lancia, S.
    Cutter, G.
    Fox, R.
    Marrie, R. A.
    Avila, R.
    Vignos, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 187 - 187
  • [26] Disease Activity as Assessed by the Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) Score Predicts Long-Term Clinical Disease Activity (CDA)-Free Status and Disability Progression in Patients Treated with Subcutaneous Interferon beta-1a (scIFNβ-1a)
    Sormani, Maria P.
    Freedman, Mark S.
    Aldridge, Julie
    Marhardt, Kurt
    De Stefano, Nicola
    [J]. NEUROLOGY, 2018, 90
  • [27] Rebif - Interferon beta-1a - SERONO - Second interferon beta-1a product for relapsing multiple sclerosis
    不详
    [J]. FORMULARY, 2002, 37 (04) : 169 - 169
  • [28] Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a
    Ebrahimimonfared, Mohsen
    Ganji, Ali
    Zahedi, Sara
    Nourbakhsh, Parisa
    Ghasami, Keyvan
    Mosayebi, Ghasem
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2018, 17 (02) : 113 - 118
  • [29] Development of an electronic injection device for subcutaneous interferon beta-1a administration in patients with relapsing multiple sclerosis
    Exell, S.
    Verdun, E.
    Driebergen, R.
    Migliaccio, M.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S203 - S203
  • [30] Effect of age on effectiveness and discontinuation of subcutaneous interferon beta-1a, and healthcare utilization, in patients with multiple sclerosis
    Sabido, M.
    Allignol, A.
    Marhardt, K.
    Vermersch, P.
    Boutmy, E.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 274 - 275
12345